drugset
drugset / Trial / NCT04643301

Liraglutide for Low-responders After Bariatric Surgery

NCT04643301 ↗

Withdrawn Zuyderland Medical Center Nederlandse Obesitas Kliniek · collab
NaSingle-groupOpen-labelOther

Summary

To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.

Timeline

Start
2020-12-21
Primary completion
2021-12-31
Completion
2021-12-31

Outcome

Outcome not reported

Stopped: “Cancellation by sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Subcutaneous

Indications

morbid obesity